Valsartan

Synonyms: CGP-48933

Valsartan is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.

Valsartan Chemical Structure

Valsartan Chemical Structure

CAS No. 137862-53-4

Purity & Quality Control

Valsartan Related Products

Biological Activity

Description Valsartan is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.
Targets
angiotensin II receptor [1]
In vitro
In vitro Valsartan dose-dependently inhibits the vasoconstriction induced by angiotensin II and lowers blood pressure in renin-dependent models of hypertension. Valsartan is at least as effective as ACE inhibitors, diuretics, beta-blockers and calcium antagonists. [1]
In Vivo
In vivo Valsartan results in improved glucose tolerance, reduced fasting blood glucose levels, and reduced serum insulin levels in mice fed a Western diet. Valsartan treatment also blocks Western diet-induced increases in serum levels of the proinflammatory cytokines interferon-gamma and monocyte chemotactic protein 1. Valsartan enhances mitochondrial function and prevents Western diet-induced decreases in glucose-stimulated insulin secretion in the pancreatic islets of mice. Valsartan treatment blocks or attenuates Western diet-induced changes in expression of several key inflammatory signals: interleukin 12p40, interleukin 12p35, tumor necrosis factor-alpha, interferon-gamma, adiponectin, platelet 12-lipoxygenase, collagen 6, inducible NO synthase, and AT1R in isolated adipocytes. [2] Valsartan significantly increases insulin-mediated 2-[3H]deoxy-d-glucose (2-[3H]DG) uptake into skeletal muscle and attenuates the increase in plasma glucose concentration after a glucose load and plasma concentrations of glucose and insulin. Valsartan treatment exaggerates the insulin-induced phosphorylation of IRS-1, the association of IRS-1 with the p85 regulatory subunit of phosphoinositide 3 kinase (PI 3-K), PI 3-K activity, and translocation of GLUT4 to the plasma membrane. Valsartan also reduces tumor necrosis factor-alpha (TNF-alpha) expression and superoxide production in skeletal muscle of KK-Ay mice. [3]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05989503 Recruiting
Heart Failure With Reduced Ejection Fraction
Universidade do Porto|Unidade de Investigação e Desenvolvimento Cardiovascular (UnIC)|Rede de Investigação em Saúde
August 4 2023 Phase 4
NCT05870709 Withdrawn
Heart Failure
Novartis Pharmaceuticals|Novartis
May 15 2023 --
NCT05564572 Enrolling by invitation
Heart Failure
Stanford University
September 7 2022 Not Applicable
NCT05194111 Recruiting
Heart Failure|Heart Dysfunction
Virginia Commonwealth University
August 11 2022 Phase 1|Phase 2

Chemical Information & Solubility

Molecular Weight 435.52 Formula

C24H29N5O3

CAS No. 137862-53-4 SDF Download Valsartan SDF
Smiles CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 87 mg/mL ( (199.76 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 87 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Valsartan | Valsartan ic50 | Valsartan price | Valsartan cost | Valsartan solubility dmso | Valsartan purchase | Valsartan manufacturer | Valsartan research buy | Valsartan order | Valsartan mouse | Valsartan chemical structure | Valsartan mw | Valsartan molecular weight | Valsartan datasheet | Valsartan supplier | Valsartan in vitro | Valsartan cell line | Valsartan concentration | Valsartan nmr